Tiber Therapeutics

Tiber Therapeutics is a biotechnology company focused on developing first-in-class small molecule inhibitors for the MYC oncogene, a master regulator of cancer cell growth and survival. Historically considered "undruggable," MYC is overexpressed in the majority of human cancers, making it a high-priority therapeutic target. The company leverages a proprietary discovery platform to identify compounds that disrupt the MYC-MAX protein-protein interaction or inhibit MYC's transcriptional activity. Their lead candidate, TIB-101, is currently in pre-clinical development for the treatment of various solid tumors and hematologic malignancies. Founded by leaders in oncology research, Tiber aims to translate decades of MYC biology into transformative medicines for patients with aggressive cancers.